245 related articles for article (PubMed ID: 31307429)
1. Evaluating pre- and post-operation plasma miRNAs of papillary thyroid carcinoma (PTC) patients in comparison to benign nodules.
Rezaei M; Khamaneh AM; Zarghami N; Vosoughi A; Hashemzadeh S
BMC Cancer; 2019 Jul; 19(1):690. PubMed ID: 31307429
[TBL] [Abstract][Full Text] [Related]
2. Altered Serum MicroRNA Profile May Serve as an Auxiliary Tool for Discriminating Aggressive Thyroid Carcinoma from Nonaggressive Thyroid Cancer and Benign Thyroid Nodules.
Zhang A; Wang C; Lu H; Chen X; Ba Y; Zhang C; Zhang CY
Dis Markers; 2019; 2019():3717683. PubMed ID: 31636734
[TBL] [Abstract][Full Text] [Related]
3. Identification of exosomal miRNA biomarkers for diagnosis of papillary thyroid cancer by small RNA sequencing.
Dai D; Tan Y; Guo L; Tang A; Zhao Y
Eur J Endocrinol; 2020 Jan; 182(1):111-121. PubMed ID: 31721725
[TBL] [Abstract][Full Text] [Related]
4. Circulating microRNA124-3p, microRNA9-3p and microRNA196b-5p may be potential signatures for differential diagnosis of thyroid nodules.
Yu S; Liu X; Zhang Y; Li J; Chen S; Zheng H; Reng R; Zhang C; Chen J; Chen L
Oncotarget; 2016 Dec; 7(51):84165-84177. PubMed ID: 27705935
[TBL] [Abstract][Full Text] [Related]
5. Circulating miR-25-3p and miR-451a May Be Potential Biomarkers for the Diagnosis of Papillary Thyroid Carcinoma.
Li M; Song Q; Li H; Lou Y; Wang L
PLoS One; 2015; 10(7):e0132403. PubMed ID: 26168287
[TBL] [Abstract][Full Text] [Related]
6. Expression Levels of miR-30a-5p in Papillary Thyroid Carcinoma: A Comparison Between Serum and Fine Needle Aspiration Biopsy Samples.
Igci YZ; Ozkaya M; Korkmaz H; Bozgeyik E; Bayraktar R; Ulasli M; Erkilic S; Eraydin A; Oztuzcu S
Genet Test Mol Biomarkers; 2015 Aug; 19(8):418-23. PubMed ID: 26047355
[TBL] [Abstract][Full Text] [Related]
7. Circulating microRNA profiles as potential biomarkers for diagnosis of papillary thyroid carcinoma.
Yu S; Liu Y; Wang J; Guo Z; Zhang Q; Yu F; Zhang Y; Huang K; Li Y; Song E; Zheng XL; Xiao H
J Clin Endocrinol Metab; 2012 Jun; 97(6):2084-92. PubMed ID: 22472564
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-222 and microRNA-146b are tissue and circulating biomarkers of recurrent papillary thyroid cancer.
Lee JC; Zhao JT; Clifton-Bligh RJ; Gill A; Gundara JS; Ip JC; Glover A; Sywak MS; Delbridge LW; Robinson BG; Sidhu SB
Cancer; 2013 Dec; 119(24):4358-65. PubMed ID: 24301304
[TBL] [Abstract][Full Text] [Related]
9. Aberrant expression of five miRNAs in papillary thyroid carcinomas.
Qiao DH; He XM; Deng X; Ji YC; Yang H; Cheng L; Zhou XY
J Clin Lab Anal; 2021 Sep; 35(9):e23907. PubMed ID: 34268792
[TBL] [Abstract][Full Text] [Related]
10. Serum microRNA profiling to distinguish papillary thyroid cancer from benign thyroid masses.
Graham ME; Hart RD; Douglas S; Makki FM; Pinto D; Butler AL; Bullock M; Rigby MH; Trites JR; Taylor SM; Singh R
J Otolaryngol Head Neck Surg; 2015 Sep; 44(1):33. PubMed ID: 26341226
[TBL] [Abstract][Full Text] [Related]
11. BCL2 and hsa-miR-181a-5p are potential biomarkers associated with papillary thyroid cancer based on bioinformatics analysis.
Zhang C; Bo C; Guo L; Yu P; Miao S; Gu X
World J Surg Oncol; 2019 Dec; 17(1):221. PubMed ID: 31842912
[TBL] [Abstract][Full Text] [Related]
12. Exosomal miRNAs are potential diagnostic biomarkers between malignant and benign thyroid nodules based on next-generation sequencing.
Pan Q; Zhao J; Li M; Liu X; Xu Y; Li W; Wu S; Su Z
Carcinogenesis; 2020 Mar; 41(1):18-24. PubMed ID: 31560760
[TBL] [Abstract][Full Text] [Related]
13. Altered expression of DLG1-AS1 distinguished papillary thyroid carcinoma from benign thyroid nodules.
He T; Wang H; Sun J; Wu J; Gong F; Li S; Wang H; Li Y
BMC Endocr Disord; 2019 Nov; 19(1):122. PubMed ID: 31718630
[TBL] [Abstract][Full Text] [Related]
14. MiR-181a-5p Regulates NIS Expression in Papillary Thyroid Carcinoma.
Gierlikowski W; Broniarek K; Cheda Ł; Rogulski Z; Kotlarek-Łysakowska M
Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34199867
[TBL] [Abstract][Full Text] [Related]
15. [Expression of microRNA-221 and IL-17 in papillary thyroid carcinoma and correlation with clinicopathologic features].
Jiang XL; Zhang H; Chen YL; Peng L
Zhonghua Bing Li Xue Za Zhi; 2017 Mar; 46(3):160-165. PubMed ID: 28297755
[No Abstract] [Full Text] [Related]
16. Differential expression levels of plasma-derived miR-146b and miR-155 in papillary thyroid cancer.
Lee YS; Lim YS; Lee JC; Wang SG; Park HY; Kim SY; Lee BJ
Oral Oncol; 2015 Jan; 51(1):77-83. PubMed ID: 25456009
[TBL] [Abstract][Full Text] [Related]
17. Discriminatory miRNAs for the Management of Papillary Thyroid Carcinoma and Noninvasive Follicular Thyroid Neoplasms with Papillary-Like Nuclear Features.
Jahanbani I; Al-Abdallah A; Ali RH; Al-Brahim N; Mojiminiyi O
Thyroid; 2018 Mar; 28(3):319-327. PubMed ID: 29378472
[TBL] [Abstract][Full Text] [Related]
18. BRAF V600E mutation and microRNAs are helpful in distinguishing papillary thyroid malignant lesions: Tissues and fine needle aspiration cytology cases.
Zarkesh M; Zadeh-Vakili A; Akbarzadeh M; Nozhat Z; Fanaei SA; Hedayati M; Azizi F
Life Sci; 2019 Apr; 223():166-173. PubMed ID: 30890403
[TBL] [Abstract][Full Text] [Related]
19. In Situ Hybridization Analysis of miR-146b-5p and miR-21 in Thyroid Nodules: Diagnostic Implications.
Guo Z; Hardin H; Montemayor-Garcia C; Asioli S; Righi A; Maletta F; Sapino A; Lloyd RV
Endocr Pathol; 2015 May; 26(2):157-63. PubMed ID: 25771986
[TBL] [Abstract][Full Text] [Related]
20. Expressions of miRNAs in papillary thyroid carcinoma and their associations with the clinical characteristics of PTC.
Hu J; Li C; Liu C; Zhao S; Wang Y; Fu Z
Cancer Biomark; 2017; 18(1):87-94. PubMed ID: 28085013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]